CONMED Corporation (CNMD) Stock Score, Valuation & Financial Research
CONMED Corporation is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 38/100.
Quick answer for CNMD
CONMED Corporation currently has a Wall Street Score of 38/100. The stored market price is $47.04. Its financial score is 26/100. Its valuation score is 30/100. The latest WSS change is +2.0 points. These figures are a research snapshot, not a buy or sell recommendation.
What CONMED Corporation does
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations. These orthopedic solutions are marketed under prominent brand names, including Hall, CONMED Linvatec, Concept, and Shutt. Furthermore, CONMED supplies general surgical equipment, encompassing items for clinical insufflation, smoke evacuati
CNMD financial snapshot
- Wall Street Score:
- 38/100
- Current price:
- $47.04
- Market capitalization:
- $1.41B
- Revenue:
- $1.37B
- Net income:
- $56.5M
- Free cash flow:
- $150.9M
- Cash:
- $37.3M
- Total debt:
- $834.2M
- EPS:
- 1.85
- P/E ratio:
- 25.4x
- Financial score:
- 26/100
- Valuation score:
- 30/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $150.9M, showing positive cash generation.
- The balance sheet shows $37.3M of cash versus $834.2M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +2.0 points: CNMD increased 2 points because Capital improved by 2 points, Valuation improved by 7.9 points.
What the numbers mean
Its current valuation score is 30/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 26/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-17.
How to research CNMD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.